Summit Therapeutics (SMMT) Return on Capital Employed (2016 - 2024)
Summit Therapeutics filings provide 10 years of Return on Capital Employed readings, the most recent being 52.87% for Q4 2024.
- Quarterly Return on Capital Employed rose 26748.0% to 52.87% in Q4 2024 from the year-ago period, while the trailing twelve-month figure was 52.87% through Dec 2024, up 26748.0% year-over-year, with the annual reading at 81.43% for FY2024, 6613.0% up from the prior year.
- Return on Capital Employed hit 52.87% in Q4 2024 for Summit Therapeutics, up from 54.11% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 19.43% in Q4 2022 and bottomed at 519.99% in Q3 2023.
- Average Return on Capital Employed over 5 years is 125.7%, with a median of 87.23% recorded in 2022.
- The largest annual shift saw Return on Capital Employed tumbled -44848bps in 2023 before it soared 46589bps in 2024.
- Summit Therapeutics' Return on Capital Employed stood at 86.05% in 2020, then fell by -5bps to 90.34% in 2021, then surged by 78bps to 19.43% in 2022, then tumbled by -1549bps to 320.35% in 2023, then soared by 83bps to 52.87% in 2024.
- Per Business Quant, the three most recent readings for SMMT's Return on Capital Employed are 52.87% (Q4 2024), 54.11% (Q3 2024), and 133.2% (Q2 2024).